Targeted clinical focus BrainPulse platform offers non-invasive skull motion measurement tied to pulsatile blood flow, with current FDA clearance for cranial motion; potential upsell to neurology and trauma centers focusing on concussion, stroke, aneurysm, AVM, and vasospasm assessment.

Expansion opportunities Small to mid-size medical device company with 11-50 employees and $1M-$10M revenue, backed by $11M funding, indicating potential for incremental investment in market expansion, clinical studies, and broader indications in neurology.

Tech-enabled selling Tech stack signals a web-driven, data-rich product narrative; leverage digital marketing, case studies, and clinical data to accelerate awareness among hospitals, clinics, and research centers.

Clinical data assets Extensive clinical experience across concussion, stroke, aneurysm, AVM, and vasospasm provides a portfolio of use cases and real-world evidence to support value propositions, training, and reimbursement discussions.

Competitive positioning Compared to peers of similar size with varied revenue, Jan Medical’s FDA-cleared cranial motion device positions it as a differentiated neurology-focused, non-invasive solution, suitable for partnerships, pilot programs, and early-adopter facilities.